- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05786365
Comparison of Emergence/Dysphoric Reaction Frequency of Using 2 Different Doses Ketamine
December 10, 2023 updated by: çağrı türkücü, Aksaray University Training and Research Hospital
Comparison of Emergence/Dysphoric Reaction Frequency of Using Ketamine at 2 Different Doses in Interventional Sedation and Analgesia
The aim of this study is to compare the effect of using different doses of ketamine on producing dysphoric reaction.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Our study is a randomized single-blind observational study.
In our study, the effect of producing a dysphoric reaction will be observed by administering ketamine at doses of 0.5 mg/kg and 1 mg/kg to two randomly randomized different groups who presented to our hospital and needed interventional sedation analgesia.
For this reason, our patients with an indication for interventional sedation and analgesia will be taken to the observation room and their vital values will be monitored.
Two different vascular accesses with at least 18 gauge will be obtained from the two extremities.
The patients will be randomized and 0.5 mg/kg IV ketamine will be given to the 1st group.
The second group will be given 1 mg/kg IV ketamine.
Then, the patients will be recorded in terms of blood pressure, pulse and saturation at the 5th minute, 15th minute and 30th minute.
We will give iv ketamine to two different patient groups as 0.5 mg per kilogram in the 1st group and 1 mg per kilogram in the 2nd group and we will observe the patients.We scored the patients between +4 and -5 points on the RASS scale.
Patients who were sedated to an extent that they could not be awakened were scored as -5, patients who were dangerously agitated +4, and patients who were awake were scored 0. We considered patients who scored +2 on the Richmond agitation sedation scale as having developed a dysphoric reaction.
Study Type
Observational
Enrollment (Estimated)
108
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aksaray, Turkey
- Çağrı Türkücü
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Cases with an indication for sedation analgesia, who applied to our emergency department, will be included in our study.
Indications for interventional sedation and analgesia: Tube thoracostomy insertion, central venous catheter insertion, fracture/dislocation reduction, skin incision repair, arthrocentesis, lumbar puncture, paracentesis, burn debridement, cardioversion
Description
Inclusion Criteria:
- Glaskow coma scale should be 15
- Inability to speak, read or understand English or Turkish
- Patients needing procedural sedation and analgesia
Exclusion Criteria:
- Patients with active coronary artery disease
- Patients with liver or kidney transplant
- Patients with conditions that change consciousness such as substance intake, alcohol intake
- Patients with advanced COPD or Heart failure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
The group given 0.5 mg/kg ketamine
In this group we will give 0.5 mg/kg ketamine and we observe for disphoric reaction
|
Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg
Other Names:
|
The group given 1 mg/kg ketamine
In this group we will give 1 mg/kg ketamine and we observe for disphoric reaction
|
Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To observe a significant difference between the two doses in terms of producing a dysphoric reaction
Time Frame: January 2023-August 2023
|
We will give iv ketamine to two different patient groups as 0.5 miligram/kilogram in the 1st group and 1 miligram/kilogram in the 2nd group and we will observe the patients.We scored the patients between +4 and -5 points on the Richmond Agitation and Sedation Scale between -5 to +4.
Patients who were sedated to an extent that they could not be awakened were scored as -5, patients who were dangerously agitated +4, and patients who were awake were scored 0. We considered patients who scored +2 on the Richmond agitation sedation scale as having developed a dysphoric reaction.
|
January 2023-August 2023
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of 0.5 mg/kg and 1 mg/kg IV ketamine
Time Frame: January 2023-August 2023
|
We will give iv ketamine to two different patient groups as 0.5 miligram/kilogram in the 1st group and 1 miligram/kilogram in the 2nd group, and and we will evaluate patients in terms of sedation duration and efficacy.We evaluated the efficacy according to whether additional doses were needed, sedation duration, and the ability to perform the procedural procedure.
|
January 2023-August 2023
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparision side effect of iv ketamine between 2 different dose group
Time Frame: January 2023-August 2023
|
We will give iv ketamine to two different patient groups as 0.5 miligram/kilogram in the 1st group and 1 miligram/kilogram in the 2nd group, and we will observe the patients in terms of the incidence of side effects.We monitored patients for the following side effects:Hypertension(Defined as a systolic blood pressure (SBP) of 140 mm Hg or more),tachycardia (Heart rate of more than 100 beats per minute),diplopia or nystagmus, nausea and vomiting, respiratory depression (apnea occurring over 10 seconds or oxygen saturation falling below 90%)
|
January 2023-August 2023
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Kamil Kokulu, M.D., Aksaray UTRH
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2023
Primary Completion (Actual)
September 15, 2023
Study Completion (Estimated)
December 31, 2023
Study Registration Dates
First Submitted
February 22, 2023
First Submitted That Met QC Criteria
March 24, 2023
First Posted (Actual)
March 27, 2023
Study Record Updates
Last Update Posted (Estimated)
December 18, 2023
Last Update Submitted That Met QC Criteria
December 10, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Ketamine
Other Study ID Numbers
- cagriturkucu
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sedation Complication
-
Samsun UniversityRecruitingSedation Complication | Procedural Sedation | Endoscopic UltrasonographyTurkey
-
Anesthesia Research Group UACompletedSedation ComplicationUkraine
-
Universitätsklinikum Hamburg-EppendorfCompletedSedation Complication
-
Peking University People's HospitalUnknownSedation ComplicationChina
-
Kocaeli Derince Education and Research HospitalUnknownSedation ComplicationTurkey
-
Sindh Institute of Urology and TransplantationCompletedSedation ComplicationPakistan
-
Rabin Medical CenterUnknownSedation ComplicationIsrael
-
Washington University School of MedicineActive, not recruitingSleep | Sedation ComplicationUnited States
-
Peking UniversityCompletedKetamine | Sedation Complication | FentanylChina
-
Peking UniversityCompletedSedation Complication | Remimazolam | MidazolamChina
Clinical Trials on Ketalar 50 MG/ML Injectable Solution
-
AstraZenecaCompletedSafety, Pharmacokinetics, Pharmacodynamics, Food EffectUnited Kingdom
-
Hermina Heart Center KemayoranUnknownRadial Artery InjuryIndonesia
-
Rare Disease Research, LLCSarepta Therapeutics, Inc.TerminatedDuchenne Muscular DystrophyUnited States
-
Faculty of Medicine, SousseUnknown
-
National Institute of Neurology and Neurosurgery...UnknownTreatment Resistant DepressionMexico
-
University Hospital MuensterVifor PharmaTerminatedAnemia | Orthopedic Surgery | High Risk of Blood LossGermany
-
UNC Lineberger Comprehensive Cancer CenterRecruiting
-
Universitair Ziekenhuis BrusselActive, not recruiting
-
University of LiegeCentre Hospitalier Universitaire de Liege; William Lennox Neurological Center...RecruitingDisorder of ConsciousnessBelgium
-
Queensland Centre for Gynaecological CancerGlaxoSmithKline Research & Development LimitedNot yet recruitingMmr Deficiency | Endometrial Cancer Stage I | Immune-related Adverse Event | Endometrioid Endometrial AdenocarcinomaAustralia